New anti-obesity pills threaten Eli Lilly and Novo Nordisk’s stock market empire
As more pharmaceutical companies make inroads in the weight loss market, the two firms saw their shares fall more than 10% in the last month
Big Pharma’s dogfight to dominate the anti-obesity market
Around the world, 100 companies have debuted weight-loss medications, which have become a multimillion-dollar business. Novo Nordisk’s Ozempic is currently the best-known, but it’s far from the only option
Hollywood has ‘Ozempic face’: Why you can look 10 years older after going all in on the slimming drug
The semaglutide craze is a global phenomenon, but among its unwanted side effects is a premature aging of the face. Health professionals have found themselves administering anti-aging treatments to an ever-younger clientele
Are European stocks finally outperforming Wall Street?
European share prices started the year on a positive note, trading at lower valuations, but analysts caution against confirming a trend shift
Ozempic, or how the weight loss company has injected $560 billion into Novo Nordisk and Eli Lilly since 2023
Citi estimates that the fight against obesity will generate revenue of $158 billion in 2035. The main risk for the sector is the difficulty in guaranteeing supply
Predictions for 2024: Trump, Biden, bitcoin, X bankruptcy, Barbie and Taylor Swift
Kiko Llaneras’ predictions for the coming year, covering world elections, economy, technology, entertainment and geopolitics
The economic disaster of extra pounds: Pharmaceutical companies are profiting in an increasingly obese world
The economic impact of obesity will reach losses of up to $4 trillion by 20235, or 3% of global GDP
Anti-obesity drugs Ozempic and Mounjaro can shrink more than patients
During trials, patients showed reduced appetite and even an aversion towards food generally. This has the potential to affect giant companies such as Nestlé and Cadbury
Novo Nordisk’s meteoric rise: The fight against obesity wins over investors
The Danish pharmaceutical company has become the most valuable business in Europe thanks to its products that combat the disease, which the WHO believes has ‘acquired pandemic proportions’
Ten drugs targeted for Medicare price negotiations as Biden pitches cost reductions
The drugs include the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications
Ozempic, the weight-loss treatment with potential to end alcohol addiction
In recent years, many patients who inject GLP-1 agonists have claimed to have lost their desire to drink. Now studies explain the scientific basis behind their experience, opening the door to other addiction treatments
Novo Nordisk plans price cuts for several insulins
AP|
The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions